NCT02261883 - Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2015

Primary Completion Date

September 27, 2022

Study Completion Date

May 17, 2023

Conditions

Persistent Pulmonary Hypertension of the Newborn

Interventions

DRUG

IV Remodulin

Treprostinil is a chemically stable tricyclic analogue of prostacyclin.

DRUG

Placebo

Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).

Trial Locations (14)

Johns Hopkins Hospital, Baltimore

University of Virginia Health Systems (UVA), Charlottesville

All Children's Hospital, St. Petersburg

University of Mississippi Medical Center - Baston Children's Hospital, Jackson

Nationwide Childrens Hospital, Columbus

Children's Hospital of Wisconsin, Wauwatosa

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

Children's Mercy Hospital, Kansas City

Arkansas Children's Hospital, Little Rock

Cook Children's Medical Center, Fort Worth

Children's Hospital of Los Angeles, Los Angeles

Stanford Children's Hospital, Palo Alto

Seattle Children's Hospital, Seattle

Columbia University Medical Center, New York